#BEGIN_DRUGCARD DB08905

# AHFS_Codes:
Not Available

# ATC_Codes:
L02BG02

# Absorption:
Poor oral bioavailability

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Lentaron

# CAS_Registry_Number:
566-48-3

# ChEBI_ID:
Not Available

# Chemical_Formula:
C19H26O3

# Chemical_IUPAC_Name:
(1S,2R,10R,11S,15S)-6-hydroxy-2,15-dimethyltetracyclo[8.7.0.0ยฒ,โ?ท.0ยนยน,ยนโ?ต]heptadec-6-ene-5,14-dione

# Chemical_Structure:
Not Available

# Creation_Date:
2013-06-13 22:20:07 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Formestane is a selective, type I, steroidal aromatase inhibitor. It is used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women. Formestane is often used to suppress estrogen production from anabolic steroids or prohormones. It also acts as a prohormone to 4-hydroxytestosterone, an active steroid which displays weak androgenic activity in addition to acting as a mild aromatase inhibitor. Formestane has poor oral bioavailability and as such is no longer popular as many orally active aromatase inhibitors have been identified. [Wikipedia]

# Dosage_Forms:
Not Available

# Drug_Category:
Antineoplastic Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
7873457	Perez Carrion R, Alberola Candel V, Calabresi F, Michel RT, Santos R, Delozier T, Goss P, Mauriac L, Feuilhade F, Freue M, et al.: Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol. 1994;5 Suppl 7:S19-24.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Formestane

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C19H26O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,22H,3-10H2,1-2H3/t11-,12-,13-,18+,19-/m0/s1

# InChI_Key:
InChIKey=OSVMTWJCGUFAOD-KZQROQTASA-N

# Indication:
For the treatment of estrogen-receptor positive breast cancer in post-menopausal women.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D07260

# LIMS_Drug_ID:
8921

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
302.4079

# Molecular_Weight_Mono:
302.188194698

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
2.57

# Predicted_LogS:
-3.7

# Predicted_Water_Solubility:
5.78e-02 g/l

# Primary_Accession_No:
DB08905

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(O)C(=O)CC[C@]12C

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
4-hydroxyandrost-4-ene-3,17-dione

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-06-13 22:28:16 -0600

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

#END_DRUGCARD DB08905
